Kiora Pharmaceuticals (KPRX) EBT Margin (2016 - 2024)

Kiora Pharmaceuticals' (KPRX) quarterly EBT Margin came in at 11108.23% in Q2 2024, down 13311.1% quarter-over-quarter from 84.08% in Q1 2024.

Analysis

Kiora Pharmaceuticals (KPRX) EBT Margin (2016 - 2024) Analysis & Trends

Kiora Pharmaceuticals (KPRX) has reported EBT Margin for 6 consecutive years, with 11108.23% the latest figure, recorded in Q2 2024.

For the quarter ending Q2 2024, EBT Margin changed N/A year-over-year to 11108.23%; the trailing twelve-month figure through Mar 2025 stood at 49317.22% (down 4933549.0% YoY), and the FY2024 full-year result was 35.33%, changed N/A from the prior year.
EBT Margin declined to 11108.23% in Q2 2024 per KPRX's latest filing, from 84.08% in the prior quarter.
Across five years, EBT Margin topped out at 84.08% in Q1 2024 and bottomed at 11108.23% in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Johnson & Johnson	663.08 Bn	642.33 Bn	17.26 Bn	26.66%
2	AbbVie	453.04 Bn	446.51 Bn	12.70 Bn	25.18%
3	Merck	370.87 Bn	363.78 Bn	12.21 Bn	-4.11%
4	Novartis Ag	305.29 Bn	298.00 Bn	11.24 Bn	29.63%
5	Pfizer	162.10 Bn	150.70 Bn	10.94 Bn	-4.34%
6	Sanofi	53.95 Bn	46.98 Bn	10.79 Bn	12.17%
7	Revolution Medicines	45.00 Bn	45.00 Bn	-	-
8	Incyte	25.47 Bn	20.94 Bn	1.57 Bn	44.89%
9	United Therapeutics	20.81 Bn	18.15 Bn	683.80 Mn	47.58%
10	Kiora Pharmaceuticals	15.75 Mn	15.75 Mn	-	-

Historic Data

Download Data